Cargando…

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients

OBJECTIVE: The RAINBOW survey is a multinational observational study assessing the tolerability and efficacy of ritonavir-boosted saquinavir (SQV/r), using the 500 mg film-coated SQV formulation, in routine clinical practice. This analysis presents data from the German subgroup of protease inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stephan, C, Jaeger, H, Carganico, A, Knecht, G, Lutz, T, Mayr, C, Mosthaf, FA, Koeppe, S, Mueller, M, Wolf, E, Tappe, A, Wellmann, E, Knechten, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351903/ https://www.ncbi.nlm.nih.gov/pubmed/20952345 http://dx.doi.org/10.1186/2047-783X-15-9-369

Ejemplares similares

The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infected patients
por: Knechten, H, et al.
Publicado: (2011)

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
por: Knechten, Heribert, et al.
Publicado: (2010)

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
por: Wiesmann, Frank, et al.
Publicado: (2011)

Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment
por: Dallas, Shannon, et al.
Publicado: (2013)

New-Onset Saquinavir-Induced Diabetes
por: van Zoelen, Marieke A.D., et al.
Publicado: (2013)

Short-Term Administration of HIV Protease Inhibitor Saquinavir Improves Skull Bone Healing with Enhanced Osteoclastogenesis
por: Liu, Haixia, et al.
Publicado: (2022)

Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug
por: Jayaswal, Amit, et al.
Publicado: (2014)

The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines
por: Bandiera, Elisabetta, et al.
Publicado: (2016)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro
por: Adamo, Riccardo, et al.
Publicado: (2013)

Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro
por: Brilhante, Raimunda Sâmia Nogueira, et al.
Publicado: (2015)

Tratamiento con saquinavir + zalcitabina + zidovudina vs saquinavir + lamivudina + zidovudina en pacientes con SIDA sin tratamiento previo
por: Jaimes Martínez, Marcos
Publicado: (2000)

Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients
por: Julio, Montaner SG, et al.
Publicado: (2006)

Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA
por: Bello, Martiniano, et al.
Publicado: (2020)

Understanding Drug Resistance of Wild-Type and L38HL Insertion Mutant of HIV-1 C Protease to Saquinavir
por: Venkatachalam, Sankaran, et al.
Publicado: (2023)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir
por: Walters, Giles, et al.
Publicado: (2015)

Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
por: Zhang, Guanghua, et al.
Publicado: (2018)

Saquinavir-Piperine Eutectic Mixture: Preparation, Characterization, and Dissolution Profile
por: Fandaruff, Cinira, et al.
Publicado: (2023)

Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles
por: Kigen, Gabriel, et al.
Publicado: (2018)

Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection
por: Pires, David, et al.
Publicado: (2021)

Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching
por: Kim, Min Jung, et al.
Publicado: (2015)

Evaluation of Lipid Profile and Intima Media Thickness in Antiretroviral-Experienced HIV-Infected Patients Treated with Protease Inhibitor-Based Regimens versus Protease Inhibitor-Sparing Regimens
por: Martini, Salvatore, et al.
Publicado: (2023)

In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice
por: Sarkar, Ambalika, et al.
Publicado: (2020)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4(+) immune cells
por: Yang, Sidi, et al.
Publicado: (2013)

The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9
por: Tong, Yao, et al.
Publicado: (2021)

Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation
por: Rana, Nilottam, et al.
Publicado: (2022)

Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients
por: Boffito, Marta, et al.
Publicado: (2015)

Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America
por: Caro-Vega, Yanink, et al.
Publicado: (2018)

Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient
por: Erba, Andrea, et al.
Publicado: (2023)

Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells
por: Pereira, Mariana, et al.
Publicado: (2022)

Synthesis of biogenic gold nano conjugate for increased efficacy and sustained drug release profile of saquinavir
por: Kesarkar, Rohan, et al.
Publicado: (2014)

Enhanced intestinal lymphatic absorption of saquinavir through supersaturated self-microemulsifying drug delivery systems
por: Jo, Kanghee, et al.
Publicado: (2020)

Defective Hydrophobic Sliding Mechanism and Active Site Expansion in HIV-1 Protease Drug Resistant Variant Gly48Thr/Leu89Met: Mechanisms for the Loss of Saquinavir Binding Potency
por: Goldfarb, Nathan E., et al.
Publicado: (2014)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Towards an ideal antiretroviral regimen for the global HIV epidemic
por: Grinsztejn, Beatriz, et al.
Publicado: (2017)

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
por: Campo, R., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0fqam6fk15qsd0tmijjfqkqbse